Xencor, Inc. XNCR 深 滬
已收盤 06-05 16:00:00 美东时间
11.77
-0.240
-2.00%
華盛通- 最 高12.08
- 今 開12.08
- 成交量 86.26万股
- 最 低 11.55
- 昨 收 12.01
- 總市值 8.73亿
- 52周最高 18.69
- 市盈率 靜 --
- 換手率 1.16%
- 52周最低 6.92
- 委 比 -64.40%
- 總股本 7414.16万
- 歷史最高 58.345
- 量 比 1.23
- 振 幅 4.41%
- 歷史最低 5.75
- 每 手 1
- 風險率 2.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial
Incyte’s (INCY) immunotherapy Monjuvi, developed with Xencor (XNCR), will soon become a first-line option for a common type of lymphoma after late-stage trial data indicated on Saturday that the CD19-...
05-31 01:46
MindWalk publishes Discovery-to-Clinic presentation factsheet
MindWalk publishes Discovery-to-Clinic presentation factsheet MindWalk Holdings published a Discovery-to-Clinic presentation detailing more than 20 partner-owned drug candidates originating from its antibody discovery work, including 10 programs in active Phase 1-3 clinical trials. Highlighted clini
05-18 20:36
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
This SAP Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Top Wall Street analysts changed outlook on top names. See analyst rating changes, including upgrades/downgrades/initiations, on Benzinga.
03-25 00:02
JP Morgan Downgrades Xencor to Neutral, Lowers Price Target to $13
JP Morgan analyst Brian Cheng downgrades Xencor (NASDAQ:XNCR) from Overweight to Neutral and lowers the price target from $18 to $13.
03-24 20:08
Xencor, Genentech to End Protein Therapeutics Collaboration
Xencor ( ($XNCR) ) just unveiled an update. Xencor, Inc., a biopharmaceutical d...
03-10 04:46
Xencor shares are trading lower after Alexion Pharmaceuticals informed the company it does not owe additional royalties for Ultomiris sales in the U.S.
Xencor shares are trading lower after Alexion Pharmaceuticals informed the comp...
03-06 01:02
Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor
Alexion refuses to pay Xencor for U.S. Ultomiris sales. Read Xencor's response and the new 2028 operating runway details.
03-05 19:00
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
